Below are the most recent publications written about "Kallikreins" by people in Profiles.
-
Teuber-Hanselmann S, Rekowski J, Vogelgsang J, von Arnim C, Reetz K, Stang A, Jöckel KH, Wiltfang J, Esselmann H, Otto M, Tumani H, Herring A, Keyvani K. CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2020 01; 91(1):40-48.
-
Nyame YA, Wilkins L, Greene DJ, Ganesan V, Dai C, Almassi N, Stephenson AJ, Gong M, Berglund R, Klein EA. Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):617-623.
-
McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, Trinh QD, Chang SL, Harshman LC, Ross AE, Pienta KJ, Lin DW, Ellis WJ, Montgomery B, Chang P, Wagner AA, Bubley GJ, Kibel AS, Taplin ME. Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. J Clin Oncol. 2019 04 10; 37(11):923-931.
-
Andriole GL, Kostakoglu L, Chau A, Duan F, Mahmood U, Mankoff DA, Schuster DM, Siegel BA. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. J Urol. 2019 02; 201(2):322-331.
-
Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJM, Morales-Barrera R, Villa-Guzmán JC, Hernando S, Rodriguez-Vida A, González-Del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 03; 75(3):368-373.
-
Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR, Shipley WU, Sandler HM. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018 11; 19(11):1504-1515.
-
Preston MA, Gerke T, Carlsson SV, Signorello L, Sjoberg DD, Markt SC, Kibel AS, Trinh QD, Steinwandel M, Blot W, Vickers AJ, Lilja H, Mucci LA, Wilson KM. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. Eur Urol. 2019 03; 75(3):399-407.
-
Maines F, De Giorgi U, Procopio G, Facchini G, Fratino L, Sabbatini R, Gasparro D, Basso U, Mosillo C, Campadelli E, Massari F, Sava T, Sirotova S, Messina C, Scagliarini S, Conteduca V, Verzoni E, Rossetti S, Veccia A, Kinspergher S, Caffo O. Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. Future Oncol. 2018 Nov; 14(26):2691-2699.
-
Kim SP, Shah ND, Meropol NJ, Tilburt JC, Nguyen PL, Yu JB, Abouassaly R, Kim A, Gross CP. Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Eur Urol Oncol. 2019 03; 2(2):189-195.
-
Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 02; 75(2):285-293.